Abstract
Triple negative breast cancer (TNBC) is one of the most aggressive cancers diagnosed amongst women with a high rate of treatment failure and a poor prognosis. Mitochondria have been found to be key players in oncogenesis and tumor progression by mechanisms such as altered metabolism, reactive oxygen species (ROS) production and evasion of apoptosis. Therefore, mitochondrial infusion is an area of interest for cancer treatment. Studies in vitro and in vivo demonstrate mitochondrial-mediated reduction in glycolysis, enhancement of oxidative phosphorylation (OXPHOS), reduction in proliferation, and an enhancement of apoptosis as effective anti-tumor therapies. This review focuses on mitochondrial dysregulation and infusion in malignancies, such as TNBC.
Funding Information
  • National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH) (R01DK117183, DK132230)
  • James D. Eason Transplant Institute
  • National Cancer Institute (R01CA253329, R01CA262112, U01CA272541)
  • Medical Student Research Fellowship

This publication has 46 references indexed in Scilit: